文献速递治疗药物监测与药物基因组学特殊人群用药

低白蛋白血症时泊沙康唑浓度的校正方法

Correction of posaconazole concentrations for hypoalbuminemia.
PubMed 文献 · Pharmacotherapy · 2025-04-18

该研究基于危重症患者泊沙康唑药代动力学数据,回顾性分析78对总浓度与游离浓度,发现白蛋白浓度显著影响治疗药物监测结果的解读。提出校正方程Ccorr=Ct/(0.01+0.99·Alb/4.4)及简化式Csim=Ct·4.4/Alb,用于将总浓度标准化至白蛋白4.4 g/dL,避免低白蛋白血症患者因总浓度偏低而误增剂量导致毒性。

要点

  • 泊沙康唑蛋白结合率>98%,低白蛋白血症时总浓度降低但游离浓度不变。
  • 建议用Ccorr=Ct/(0.01+0.99·Alb/4.4)校正总浓度至白蛋白4.4 g/dL。
  • 低白蛋白血症患者总浓度在治疗范围内更可能提示毒性,尤其增量后。

核心结论

  • 低白蛋白血症与泊沙康唑总浓度降低相关,但活性游离浓度预计不会系统性改变。
  • 低白蛋白血症患者总浓度处于治疗范围时更可能伴随毒性,尤其为达治疗浓度而增加剂量时。

研究设计与样本

  • 回顾性分析危重症患者泊沙康唑药代动力学研究中获取的游离与总浓度数据。
  • 共纳入78对总浓度与游离浓度,采用UHPLC-MS/MS测定。

主要发现

  • 游离分数中位数为0.00645(四分位距0.00331-0.00794)。
  • 白蛋白浓度对治疗药物监测结果的解读有高度显著作用。

关键数值与推荐

  • 校正方程Ccorr=Ct/(0.01+0.99·Alb/4.4),其中Ct为总浓度,Alb为白蛋白浓度(g/dL)。
  • 简化近似方程Csim=Ct·4.4/Alb,为Ccorr的近似值。

临床怎么用

  • 对低白蛋白血症患者解读泊沙康唑总浓度时,建议使用校正方程标准化至白蛋白4.4 g/dL。
  • 避免仅因总浓度偏低而增加剂量,以防游离浓度过高导致毒性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Posaconazole is an example of a highly protein-bound drug (>98%) in which therapeutic drug monitoring (TDM) is commonplace. Total drug concentration is typically measured, and in the setting of hypoalbuminemia, total concentrations are lower despite no anticipated change in unbound concentration. Data support that unbound posaconazole concentration is responsible for antifungal activity and, in theory, is responsible for adverse effects that are dose-related. However, the therapeutic range of posaconazole is expressed as total concentration. The objective of this study was to investigate the use of an equation to correct posaconazole concentrations for albumin concentration as a surrogate for measurement of unbound concentration. METHODS: Data on unbound and total posaconazole concentration were acquired retrospectively from a study of posaconazole pharmacokinetics in critically ill patients. The relationship between total and unbound concentration was explored with and without albumin as a covariate using linear regression. Correction equations were used to normalize total concentration to an albumin concentration of 4.4 g/dL. RESULTS: A total of 78 pairs of total and unbound concentrations were available. Total and unbound posaconazole concentrations were determined using ultra-high-performance liquid chromatography-tandem mass spectrometry (UHPLC-MS/MS). The median fraction unbound was 0.00645 (interquartile range of 0.00331-0.00794). Albumin concentration plays a highly significant role in the interpretation of TDM results. In a patient with hypoalbuminemia, a corrected concentration (Ccorr) = Ct/(0.01 + 0.99·Alb/4.4), where Ct is the total concentration and Alb is the albumin concentration in units of g/dL, is suggested. This equation can be further simplified to Csim = Ct·4.4/Alb, where Csim is a close approximation of Ccorr. CONCLUSIONS: Hypoalbuminemia is associated with lower total concentrations of posaconazole; however, the "active" unbound concentration is not expected to systematically change. As a result, total posaconazole concentrations in the therapeutic range for patients with hypoalbuminemia are more likely to be associated with toxicity, especially when doses are increased to achieve "therapeutic" concentrations.

来源:Pharmacotherapy,查看原文。版权归原作者所有。

引用

  1. Nix DE, Sime F, Roberts JA, et al. Correction of posaconazole concentrations for hypoalbuminemia. Pharmacotherapy. 2025. PMID: 40251837. doi:10.1002/phar.70021

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。